161 related articles for article (PubMed ID: 30930112)
21. c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell Line.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Tsumura H
PLoS One; 2015; 10(9):e0138560. PubMed ID: 26393798
[TBL] [Abstract][Full Text] [Related]
22. miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAP1B.
Wang C; Wu C; Yang Q; Ding M; Zhong J; Zhang CY; Ge J; Wang J; Zhang C
Oncotarget; 2016 Nov; 7(45):73888-73902. PubMed ID: 27729617
[TBL] [Abstract][Full Text] [Related]
23. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.
Mastropasqua F; Marzano F; Valletti A; Aiello I; Di Tullio G; Morgano A; Liuni S; Ranieri E; Guerrini L; Gasparre G; Sbisà E; Pesole G; Moschetta A; Caratozzolo MF; Tullo A
Mol Cancer; 2017 Mar; 16(1):67. PubMed ID: 28327152
[TBL] [Abstract][Full Text] [Related]
24. Decreased miR-200a-3p is a key regulator of renal carcinoma growth and migration by directly targeting CBL.
Ding M; Sun X; Zhong J; Zhang C; Tian Y; Ge J; Zhang CY; Zen K; Wang JJ; Zhang C; Wang C
J Cell Biochem; 2018 Dec; 119(12):9974-9985. PubMed ID: 30171729
[TBL] [Abstract][Full Text] [Related]
25. A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1.
Hollander D; Donyo M; Atias N; Mekahel K; Melamed Z; Yannai S; Lev-Maor G; Shilo A; Schwartz S; Barshack I; Sharan R; Ast G
Genome Res; 2016 Apr; 26(4):541-53. PubMed ID: 26860615
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma.
Li X; Xin S; He Z; Che X; Wang J; Xiao X; Chen J; Song X
Cell Physiol Biochem; 2014; 33(6):1631-42. PubMed ID: 24902663
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention.
Karmakar S; Kaushik G; Nimmakayala R; Rachagani S; Ponnusamy MP; Batra SK
Semin Cancer Biol; 2019 Feb; 54():63-71. PubMed ID: 29199014
[TBL] [Abstract][Full Text] [Related]
28. miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS.
Neu J; Dziunycz PJ; Dzung A; Lefort K; Falke M; Denzler R; Freiberger SN; Iotzova-Weiss G; Kuzmanov A; Levesque MP; Dotto GP; Hofbauer GFL
PLoS One; 2017; 12(9):e0185028. PubMed ID: 28931048
[TBL] [Abstract][Full Text] [Related]
29. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
[TBL] [Abstract][Full Text] [Related]
30. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
31. c-Myc modulates glucose metabolism via regulation of miR-184/PKM2 pathway in clear-cell renal cell carcinoma.
Huang J; Kong W; Zhang J; Chen Y; Xue W; Liu D; Huang Y
Int J Oncol; 2016 Oct; 49(4):1569-75. PubMed ID: 27431728
[TBL] [Abstract][Full Text] [Related]
32. miR-200c inhibits breast cancer proliferation by targeting KRAS.
Song C; Liu LZ; Pei XQ; Liu X; Yang L; Ye F; Xie X; Chen J; Tang H; Xie X
Oncotarget; 2015 Oct; 6(33):34968-78. PubMed ID: 26392416
[TBL] [Abstract][Full Text] [Related]
33. miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W.
Wang K; Chen X; Zhan Y; Jiang W; Liu X; Wang X; Wu B
Tumour Biol; 2015 Sep; 36(9):6875-82. PubMed ID: 25846734
[TBL] [Abstract][Full Text] [Related]
34. MiR-422a regulates cellular metabolism and malignancy by targeting pyruvate dehydrogenase kinase 2 in gastric cancer.
He Z; Li Z; Zhang X; Yin K; Wang W; Xu Z; Li B; Zhang L; Xu J; Sun G; Wang L; Li Q; Huang X; Zhang L; Zhang D; Xu H; Xu Z
Cell Death Dis; 2018 May; 9(5):505. PubMed ID: 29725130
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs.
Kim EA; Kim SW; Nam J; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ
Oncotarget; 2016 May; 7(22):31832-46. PubMed ID: 27092874
[TBL] [Abstract][Full Text] [Related]
36. microRNA-7 impairs autophagy-derived pools of glucose to suppress pancreatic cancer progression.
Gu DN; Jiang MJ; Mei Z; Dai JJ; Dai CY; Fang C; Huang Q; Tian L
Cancer Lett; 2017 Aug; 400():69-78. PubMed ID: 28450156
[TBL] [Abstract][Full Text] [Related]
37. Replisome genes regulation by antitumor miR-101-5p in clear cell renal cell carcinoma.
Yamada Y; Nohata N; Uchida A; Kato M; Arai T; Moriya S; Mizuno K; Kojima S; Yamazaki K; Naya Y; Ichikawa T; Seki N
Cancer Sci; 2020 Apr; 111(4):1392-1406. PubMed ID: 31975570
[TBL] [Abstract][Full Text] [Related]
38. miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer.
Guo X; Zhu Y; Hong X; Zhang M; Qiu X; Wang Z; Qi Z; Hong X
Cell Death Dis; 2017 Jul; 8(7):e2958. PubMed ID: 28749470
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma.
Su Z; Chen D; Zhang E; Li Y; Yu Z; Shi M; Jiang Z; Ni L; Yang S; Gui Y; Ye J; Lai Y
Mol Med Rep; 2015 Jul; 12(1):1535-43. PubMed ID: 25815776
[TBL] [Abstract][Full Text] [Related]
40. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression.
Chen X; Wang X; Ruan A; Han W; Zhao Y; Lu X; Xiao P; Shi H; Wang R; Chen L; Chen S; Du Q; Yang H; Zhang X
Clin Cancer Res; 2014 May; 20(10):2617-30. PubMed ID: 24647573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
